|Report Code: PP10096||Report Type: Indication Pipeline Reports||Available format:|
Complex regional pain syndrome (CRPS) is a type of chronic pain that affects one limb of the body (hand, leg, arm, or foot). The condition generally arises due to severe injuries or malfunctioning of central and peripheral nervous systems. CRPS is categorized into two main types: CRPS-I and CRPS-II. CRPS-I is associated with unconfirmed nerve injury; whereas, CRPS-II is associated with confirmed nerve injury. CRPS can be characterized by ‘pins and needles’, or ‘burning sensation’; or it feels like someone squeezing the affected limb. People having CRPS generally experience change in skin color and temperature, and swelling in the affected area.
Axsome Therapeutics Inc., and Grünenthal Group are two major companies involved in the development of drugs for the management of CRPS. The Grünenthal Group is in the process of developing T121, a bone resorption inhibitor, for the treatment of CRPS. Axsome Therapeutics Inc. is also developing AXS-02 as a bone resorption factor inhibitor for the treatment of CRPS.